NOTV Stock Overview
Provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries in the United States, the Netherlands, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Inotiv, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.27 |
| 52 Week High | US$11.42 |
| 52 Week Low | US$1.23 |
| Beta | 3.6 |
| 1 Month Change | 4.66% |
| 3 Month Change | 142.61% |
| 1 Year Change | 17.63% |
| 3 Year Change | -84.60% |
| 5 Year Change | -20.04% |
| Change since IPO | -48.24% |
Recent News & Updates
Recent updates
Is Inotiv (NASDAQ:NOTV) A Risky Investment?
Dec 06
Inotiv, Inc.'s (NASDAQ:NOTV) 57% Dip In Price Shows Sentiment Is Matching Revenues
Apr 26Inotiv (NASDAQ:NOTV) Takes On Some Risk With Its Use Of Debt
Mar 19Inotiv, Inc.'s (NASDAQ:NOTV) Price Is Right But Growth Is Lacking After Shares Rocket 34%
Feb 13Inotiv, Inc. (NASDAQ:NOTV) Stock Rockets 61% But Many Are Still Ignoring The Company
Dec 18Earnings Release: Here's Why Analysts Cut Their Inotiv, Inc. (NASDAQ:NOTV) Price Target To US$12.81
Dec 13Is Inotiv (NASDAQ:NOTV) A Risky Investment?
Nov 21Is Inotiv (NASDAQ:NOTV) A Risky Investment?
Aug 14Is Inotiv (NASDAQ:NOTV) Using Debt In A Risky Way?
May 09Inotiv adds 16% on settlement with U.S. over Virginia facility
Jul 18Inotiv completes acquisition of bioanalytical company Protypia for ~$11M
Jul 07Shareholder Returns
| NOTV | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 1.2% | 1.5% | 3.2% |
| 1Y | 17.6% | -0.1% | 24.2% |
Return vs Industry: NOTV exceeded the US Life Sciences industry which returned -0.1% over the past year.
Return vs Market: NOTV underperformed the US Market which returned 24.2% over the past year.
Price Volatility
| NOTV volatility | |
|---|---|
| NOTV Average Weekly Movement | 21.0% |
| Life Sciences Industry Average Movement | 9.5% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 18.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: NOTV's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NOTV's weekly volatility (21%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1974 | 2,026 | Bob Leasure | www.inotivco.com |
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries in the United States, the Netherlands, and internationally. It operates through two segments, Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DMS segment manufactures scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the company’s BASi product line.
Inotiv, Inc. Fundamentals Summary
| NOTV fundamental statistics | |
|---|---|
| Market cap | US$111.08m |
| Earnings (TTM) | -US$108.44m |
| Revenue (TTM) | US$490.74m |
0.2x
P/S Ratio-1.0x
P/E RatioIs NOTV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NOTV income statement (TTM) | |
|---|---|
| Revenue | US$490.74m |
| Cost of Revenue | US$379.57m |
| Gross Profit | US$111.17m |
| Other Expenses | US$219.62m |
| Earnings | -US$108.44m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.17 |
| Gross Margin | 22.65% |
| Net Profit Margin | -22.10% |
| Debt/Equity Ratio | 230.7% |
How did NOTV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/20 09:06 |
| End of Day Share Price | 2025/01/17 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/09/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Inotiv, Inc. is covered by 5 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Matthew Hewitt | Craig-Hallum Capital Group LLC |
| David Windley | Jefferies LLC |
| Jeffrey Cohen | Ladenburg Thalmann & Company |